News & Trends - Pharmaceuticals

Lilly kicks off 2020’s biopharma M&A

Health Industry Hub | January 13, 2020 |
[Total: 1    Average: 4/5]

Eli Lilly plans to acquire Dermira, a biopharmaceutical company dedicated to developing new therapies for chronic skin conditions, for $1.1 billion.

The acquisition will expand Lilly’s immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity that is being evaluated in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients, ages 12 years and older.

Lebrikizumab was granted Fast Track designation from the U.S. Food and Drug Administration (FDA) in December 2019. The acquisition of Dermira will also expand Lilly’s portfolio of marketed dermatology medicines with the addition of QBREXZA (glycopyrronium) cloth, a medicated cloth for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating).

“People suffering from moderate-to-severe atopic dermatitis have significant unmet treatment needs, and we are excited about the potential that lebrikizumab has to help these patients,” said Patrik Jonsson, Lilly senior vice president and president of Lilly Bio-Medicines “The acquisition of Dermira is consistent with Lilly’s strategy to augment our own internal research by acquiring clinical phase assets in our core therapeutic areas and leveraging our development expertise and commercial infrastructure to bring new medicines to patients. This acquisition provides an opportunity to add a promising Phase 3 immunology compound for atopic dermatitis, while also adding an approved dermatology treatment for primary axillary hyperhidrosis.”

“Since Dermira’s inception, we have been focused on applying strong science to medical dermatology with the goal of finding new ways to treat some of the most common skin conditions that affect millions of people every year,” said Tom Wiggans, chairman and chief executive officer at Dermira. “We are pleased that Lilly has recognised the progress we have made and the opportunities for lebrikizumab and QBREXZA.”

The transaction is expected to close by the end of the first quarter of 2020.

Build thought leadership, differentiate your organisation and let us help you connect with the Australian Pharma, MedTech and Biotech industry professionals. To learn more about Health Industry Hub’s unique media solutions please contact us.

You may also like AbbVie announces new business, Allergan Aesthetics


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Social Responsibility

Social Responsibility and Community Engagement - World Cancer Day 2020

World Cancer Day 2020

Health Industry Hub | January 22, 2020 |

People across Australia will come together on 4 February to reduce the impact of cancer around the world. 2020 marks […]

More


News & Trends - Pharmaceuticals

Pharma Medical News - TGA reveals new regulatory science strategy 2020-2025

TGA reveals new regulatory science strategy 2020-2025

Health Industry Hub | January 22, 2020 |

New technologies such as gene therapies, other cell and tissue therapies, 3D-printing, and software as a medical device are transforming […]

More


Marketing & Strategy

Biopharma marketing - embracing change for growth

Biopharma marketing – embracing change for growth

Health Industry Hub | January 22, 2020 |

For years, biopharma companies have celebrated their “patient centricity”, yet only 35% of patient groups say that the industry is […]

More


News & Trends - Medical Technology

MedTech News - Medtronic to launch a game changer for patients with neurological disorders

Medtronic to launch a game changer for patients with neurological disorders

Health Industry Hub | January 22, 2020 |

Medtronic announced the CE Mark for Percept PC neurostimulator; it is the only Deep Brain Stimulation (DBS) system to be […]

More